Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Share Is Expected To Grow At A CAGR Of 13.49% By 2030

10-Jan-2023 | Facts and Factors

According to Facts and Factors, the global chimeric antigen receptor (CAR) T-Cell therapy market size was worth around USD 1.69 billion in 2021 and is predicted to grow to around USD 6 billion by 2030 with a compound annual growth rate (CAGR) of roughly 13.49% between 2022 and 2030.

Chimeric antigen receptor (CAR) T-cell therapy is one of the modern treatment methods deployed to treat cancer, one of the highest death-causing medical conditions without a 100% cure. In this therapy, T-cells, which are a type of immunity cells, are removed from cancer patients and genetically modified in laboratories. With the modification, the T-cells can bind themselves to cancer cells and kill them. The process includes blood drawn from the vein of the cancer patient. The blood passes through a tube to an apheresis machine which is required to remove the white blood cells or the T-cells. The rest of the blood is administered back to the patient’s system.

Browse the full “Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size, Share, Growth Analysis Report By End-User (Cancer Treatment Center, Hospitals, and Others), By Drug Type (Axicabtagene Ciloleucel, Brexucabtagene Autoleucel, Tisagenlecleucel, and Others), By Indication (Acute Lymphocytic Leukemia, Lymphoma, and Others), and By Region - Global and Regional Industry Insights, Overview, Comprehensive Analysis, Trends, Statistical Research, Market Intelligence, Historical Data and Forecast 2022 – 2030" report at https://www.fnfresearch.com/chimeric-antigen-receptor-car-t-cell-therapy-market

After the end of this process, a gene for a specific receptor is then inserted in the T-cells. The receptor is called the chimeric antigen receptor (CAR). The resultant CAR T-cells are then administered back to the patients. As the antigens vary depending on cancer, every CAR is created depending on the cancer antigen. Millions of CAR T-cells are modified in the lab and administered to the patient through an infusion. These modified cells can then recognize and kill the cancer cells.

The global chimeric antigen receptor (CAR) T-cell therapy market is projected to grow owing to the increase in investment in research & development of effective cancer treatments. The disease is one of the leading causes of death globally. It is difficult to completely eradicate the cells from the patient's system because cancer can start from any organ or tissue in the body and the rate at which the cancer cells expand cannot be predicted until the disease is diagnosed. These factors have led to global efforts toward developing drugs and therapies that can effectively cure the disease.

For instance, in April 2022, SoftBank Group Corporation invested USD 63 billion in a Japan-based startup that helps to detect cancer. The detection is made with the help of artificial intelligence. The cancer treatment market is full of such collaboration and partnerships which will help the global market grow further in the coming years. In June 2021, Australia invested AUD 10 million to be directed toward the development and use of CAR T-cell therapies against solid tumors.

The global market could face growth restrictions due to the therapy being effective only for certain types of cancer. Currently, with the information available about CAR T-cell therapy, it is most effective only for specific solid tumors and may prove to be ineffective for other types. The Food and Drugs Administration has presently approved the use of the revolutionary therapy to treat patients with blood cancers like lymphomas, and multiple myeloma along with certain types of leukemia.

The longer benefits could provide growth opportunities whereas the high cost of treatment may challenge market growth.

Segmental Overview

The global chimeric antigen receptor (CAR) T-cell therapy market is segmented based on end-user, drug type, indication, and region

Based on drug type, the global market divisions areaxicabtagene ciloleucel, brexucabtagene autoleucel, tisagenlecleucel, and others. In 2021, axicabtagene was the highest contributor in the global market due to the increased adoption rate of Yescarta, an areaxicabtagene ciloleucel medicine for treating cases of relapsed follicular lymphoma or large B-cell lymphoma. Annually, 6 in 100,000 people are affected by the latter condition.

Based on indication, the global market divisions are acute lymphocytic leukemia, lymphoma, and others. In the previous year, the global market was dominated by the lymphoma segment and it is projected to follow the same trend during the projection period owing to the high number of population suffering from the disease. Lymphome is one of the certain cancer conditions that has received approval from agencies to use the therapy for the treatment process. One of the most common forms of cancer in the US is non-Hodgkin lymphoma. It comprises around 4% of all cancers. The global market could also register a high CAGR for acute lymphocytic leukemia due to growing awareness about the benefits of medical treatment.

Regional Overview

North America is projected to dominate the global chimeric antigen receptor (CAR) T-cell market due to the increasing number of cancer patients in the country. As per estimates, more than 1.89 million new cases of cancer were registered in the US in 2022. It resulted in the deaths of over 609,350 people. The regional growth is likely to be driven by the high awareness rate in the medical community about the efficiency of the treatment plan. CAR T-cell therapy should only be conducted by experienced professionals due to the high associated side effects if done incorrectly. As the number of research institutes in the country is high, the population benefits from the same. Growth in Asia-Pacific is projected to be driven by the growing investment in cancer research. In December 2021, Karkinos, an India-based oncology-related startup received funding from Reliance Industries.

Report Scope

Competitive Landscape

The global chimeric antigen receptor (CAR) T-cell therapy market is led by players like Bluebird Inc., Celyad, TrakCel, Juno Therapeutics, Immune Therapeutics, Eureka Therapeutics, Ziopharm Oncology, and others.

Recent Developments:

• In May 2022, Novartis received approval from the US Food and Drugs Administration for Kymriah® , a chimeric antigen receptor (CAR) T-cell therapy
• In September 2022, the European Commission approved the use of CAR T-cell therapy developed by Kite, a Gilead Company

The global chimeric antigen receptor (CAR) T-cell therapy market is segmented as follows:

By End-User 

• Cancer Treatment Center
• Hospitals
• Others

By Drug Type 

• Axicabtagene Ciloleucel
• Brexucabtagene Autoleucel
• Tisagenlecleucel
• Others

By Indication 

• Acute Lymphocytic Leukemia
• Lymphoma
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Nordic Countries
    • Denmark
    • Sweden
    • Norway
  • Benelux Union
    • Belgium
    • The Netherlands
    • Luxembourg
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Southeast Asia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Rest of Southeast Asia
  • Rest of Asia Pacific
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America

About Us:

Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.

Contact Us:
Facts & Factors
A 2108, Sargam,
Nanded City,
Sinhagad Road,
Pune 411041, India
USA: +1 (347) 690-0211
Email: [email protected]
Web: https://www.fnfresearch.com